Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| A-192621 SCHEMBL1030269 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL7465738 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL3982388 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL22404939 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL3982386 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8176298 | 0.97 | EDNRB (0.94) | EDNRBEDNRA | |
| SCHEMBL8189498 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8189503 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8185019 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8180058 | 0.94 | EDNRB (1.00) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108025035-B | Compositions and methods for treating cancers associated with ETBR activation | ENB治疗公司 | 2023-06-13 | — | — | CN | claimed |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | ENB THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| WO-2024179362-A1 | METHODS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION SKELETAL SEQUELAE | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024141048-A1 | METHODS FOR TREATING CORONAVIRUS INFECTIONS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2024-07-04 | — | — | WO | disclosed |
| US-11338014-B2 | Methods and compositions for treatment of endothelin B receptor expressing tumors | ENB THERAPEUTICS, INC. | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11338014-B2 | Methods and compositions for treatment of endothelin B receptor expressing tumors | EDNRB, EDNRA, CASP8 | EDNRB 1/4885EDNRA 2/4885 |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | EDNRB, EDNRA, CASP8 | EDNRB 1/4885EDNRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.